NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization142.84 mln
Float12.12 mln
Earnings Date08/26/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
0.7
Highly suspicious
1-Year Forecast
14.67
Transformational upside
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-55.47
Deeply negative
Business Description
Alpha Cognition Inc. is a drug development company based in Vancouver, Canada, focused on finding new ways to treat brain and nervous system diseases across North America. Its lead product, ZUNVEYL, is an approved oral medication for Alzheimer's disease, with ongoing research exploring its use alongside other treatments for more advanced stages of the condition. The company is also working on several early-stage programs targeting conditions such as traumatic brain injury, acute pancreatitis, and rare diseases that affect muscle and nerve function.
